Qiagen (QGEN) Expected to Announce Quarterly Earnings on Wednesday

Qiagen (NYSE:QGEN) will likely be releasing its Q4 2025 results after the market closes on Wednesday, February 4th. Analysts expect Qiagen to post earnings of $0.59 per share and revenue of $528.5340 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Thursday, February 5, 2026 at 9:30 AM ET.

Qiagen (NYSE:QGEN) last announced its quarterly earnings data on Thursday, November 6th. The company reported $0.64 EPS for the quarter, beating analysts’ consensus estimates of $0.61 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The firm had revenue of $532.58 million for the quarter, compared to the consensus estimate of $525.68 million. During the same period in the previous year, the firm posted $0.60 earnings per share. The firm’s revenue was up 6.2% on a year-over-year basis. On average, analysts expect Qiagen to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Qiagen Stock Down 0.1%

QGEN stock opened at $53.63 on Monday. The company has a 50 day moving average of $49.53 and a two-hundred day moving average of $49.63. The company has a market cap of $11.33 billion, a price-to-earnings ratio of 27.69, a PEG ratio of 2.56 and a beta of 0.67. Qiagen has a 12-month low of $39.61 and a 12-month high of $57.81. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45.

Analyst Ratings Changes

Several brokerages recently issued reports on QGEN. Wall Street Zen lowered Qiagen from a “buy” rating to a “hold” rating in a report on Saturday, January 10th. Citigroup downgraded Qiagen from a “buy” rating to a “neutral” rating and cut their price target for the stock from $57.89 to $52.63 in a research note on Thursday, December 11th. Barclays reiterated an “overweight” rating and set a $57.89 price target (up from $55.79) on shares of Qiagen in a report on Monday, December 15th. UBS Group restated a “neutral” rating on shares of Qiagen in a report on Wednesday, January 21st. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Qiagen has a consensus rating of “Hold” and a consensus price target of $53.04.

Institutional Investors Weigh In On Qiagen

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Danske Bank A S bought a new stake in Qiagen during the third quarter worth approximately $36,000. Advisory Services Network LLC acquired a new stake in shares of Qiagen in the third quarter worth $64,000. EverSource Wealth Advisors LLC boosted its holdings in shares of Qiagen by 226.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock worth $125,000 after buying an additional 1,802 shares during the period. Osaic Holdings Inc. grew its stake in Qiagen by 101.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock valued at $185,000 after buying an additional 1,951 shares during the last quarter. Finally, Pitcairn Co. bought a new position in Qiagen in the 2nd quarter worth $208,000. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.